Lanean...
Is there clinical value to prognostic signatures in early stage NSCLC?
pAMPK and pmTOR favorably predicted outcome in early NSCLC. The differences were small. Phosphoprotein lability makes routine clinical use and validation difficult. Protein IHC is unlikely to be clinically useful and numerous efforts to create predictive models to select resected patients for therap...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2014
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3998101/ https://ncbi.nlm.nih.gov/pubmed/24583801 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-3387 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|